
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. demonstrates a positive outlook due to the promising sales potential of its commercial product Brinsupri, which is projected to reach peak sales of approximately $5 billion or more, supported by strong endorsements from healthcare professionals. The company's reported double-digit year-over-year growth for Brinsupri, alongside Arikayce's 19% annual growth rate, indicates robust market penetration and effective chronic disease treatment strategies. Furthermore, the anticipated revenue growth positions Insmed on a path toward cash flow positivity, alleviating concerns regarding capital dilution for investors.
Bears say
Insmed Inc has recently experienced a pullback in its stock value following the disappointing results from the Phase 2b BiRCh study for brensocatib in chronic rhinosinusitis without nasal polyps, which has negatively impacted market expectations for its future clinical outcomes. Additionally, the company faces numerous risks that could hinder its growth, including potential deceleration in the launch of Brinsupri, the challenges associated with enrolling and completing clinical studies for its key products, and the lack of animal model validation for new indications. Moreover, Insmed's ongoing high cash burn rate, reported at $165-170 million, poses a significant concern as the company attempts to scale revenue, particularly as it prepares for upcoming international launches and the results of critical trials.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares